Contemporary Considerations for Breast Cancer Risk and Screening in Transgender, Nonbinary, and Gender-Diverse Populations.

Curr Breast Cancer Rep

Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226, USA.

Published: February 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose Of Review: Breast cancer incidence, risk factors, and risk-reducing strategies are relatively well established for cisgender persons, but this information is limited in the transgender and gender-diverse (TGD) community. TGD persons have unique considerations that may affect risk, such as the need for gender-affirming hormone therapy or gender-affirming operations. This review outlines key literature informing our knowledge of breast cancer risk and summarizes screening recommendations for TGD persons.

Recent Findings: Studies informing breast cancer risk in TGD persons have significant limitations. Generally, they suggest that transgender women have a higher incidence of developing breast cancer compared to cisgender men, but a much lower incidence compared to cisgender women; and that transgender men have higher rates of breast cancer compared to cisgender men, but lower rates compared to cisgender women. Screening guidelines put forth by professional societies are based on these retrospective cohort studies, expert consensus, and extrapolation from cisgender populations. The United States Preventive Services Task Force and American Cancer Society have not yet published guidelines.

Summary: Prospective data are needed to further define risk and best practices for breast cancer screening in the TGD community, an already marginalized population susceptible to worse oncologic outcomes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12234010PMC
http://dx.doi.org/10.1007/s12609-025-00573-6DOI Listing

Publication Analysis

Top Keywords

breast cancer
28
compared cisgender
16
cancer risk
12
cancer
8
tgd community
8
tgd persons
8
cancer compared
8
cisgender men
8
men lower
8
cisgender women
8

Similar Publications

Importance: Patients with advanced cancer frequently receive broad-spectrum antibiotics, but changing use patterns across the end-of-life trajectory remain poorly understood.

Objective: To describe the patterns of broad-spectrum antibiotic use across defined end-of-life intervals in patients with advanced cancer.

Design, Setting, And Participants: This nationwide, population-based, retrospective cohort study used data from the South Korean National Health Insurance Service database to examine broad-spectrum antibiotic use among patients with advanced cancer who died between July 1, 2002, and December 31, 2021.

View Article and Find Full Text PDF

NPY-functionalized niosomes for targeted delivery of margatoxin in breast cancer therapy.

Med Oncol

September 2025

Venom and Biotherapeutics Molecules Laboratory, Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.

Neuropeptide Y (NPY) and the voltage-gated potassium channel Kv1.3 are closely associated with breast cancer progression and apoptosis regulation, respectively. NPY receptors (NPYRs), which are overexpressed in breast tumors, contribute to tumor growth, migration, and angiogenesis.

View Article and Find Full Text PDF

S100A8/A9-MCAM signaling promotes gastric cancer cell progression via ERK-c-Jun activation.

In Vitro Cell Dev Biol Anim

September 2025

Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama-shi, Okayama, 700-8558, Japan.

S100 protein family members S100A8 and S100A9 function primarily as a heterodimer complex (S100A8/A9) in vivo. This complex has been implicated in various cancers, including gastric cancer (GC). Recent studies suggest that these proteins play significant roles in tumor progression, inflammation, and metastasis.

View Article and Find Full Text PDF

Purpose: Breast cancer (BC) is the most frequent cancer among women and the second leading cause of central nervous system (CNS) metastases. While the epidemiology of CNS metastases from BC has been well described, little is known about the treatment patterns and outcomes of young women < 40 years of age with BC that is metastatic to the CNS.

Methods: In this retrospective analysis, we identified patients with metastatic breast cancer (MBC) to the CNS who were treated at the Sunnybrook Odette Cancer Center, Toronto, Canada between 2008 and 2018.

View Article and Find Full Text PDF